Nature Search

Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial

Borcoman and colleagues present the efficacy and safety results of the phase 2 PEVOsq basket trial investigating the combination of pembrolizumab with the epidrug vorinostat in patients with recurrent and/or metastatic squamous cell carcinoma.

Edith Borcoman
Bastien Cabarrou
Christophe Le Tourneau
ResearchOpen Access30 Jun 2025
Nature Cancer

Volume: 6, P: 1370-1383
Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors

Marie-Paule Sablin
Pierre Gestraud
Ivan Bièche
ResearchOpen Access02 Aug 2024
British Journal of Cancer

Volume: 131, P: 1060-1067
Genomics to select treatment for patients with metastatic breast cancer

Targeted therapies matched to genomics improved progression-free survival when genomic alterations were classified as level I/II (according to ESCAT), and genomics should thus be driven by target actionability in patients with metastatic breast cancer.

Fabrice Andre
Thomas Filleron
Ivan Bieche
Research07 Sept 2022
Nature

Volume: 610, P: 343-348
Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

Exploratory analyses from the phase 2 randomized SAFIR02-IMMUNO trial identify biomarkers associated with improved outcomes to durvalumab as compared to maintenance chemotherapy in patients with triple-negative breast cancer.

Thomas Bachelot
Thomas Filleron
Fabrice Andre
Research18 Jan 2021
Nature Medicine

Volume: 27, P: 250-255
Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis

Antoine Vasseur
Luc Cabel
François-Clément Bidard
ResearchOpen Access27 Feb 2024
Oncogene

Volume: 43, P: 1214-1222

Quick links

Search

Filter By:

Efficacy of pembrolizumab and vorinostat combination in patients with recurrent and/or metastatic squamous cell carcinomas: a phase 2 basket trial

Copy number alterations in metastatic and early breast tumours: prognostic and acquired biomarkers of resistance to CDK4/6 inhibitors

Genomics to select treatment for patients with metastatic breast cancer

Durvalumab compared to maintenance chemotherapy in metastatic breast cancer: the randomized phase II SAFIR02-BREAST IMMUNO trial

Fulvestrant and everolimus efficacy after CDK4/6 inhibitor: a prospective study with circulating tumor DNA analysis

Search

Quick links